Treatment of Waldenstrom's macroglobulinemia

Current Treatment Options in Oncology

Volumn 8, Issue 2, 2007, Pages 144-153

  Dimopoulos, Meletios A ^a   Anagnostopoulos, Athanasios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; LENALIDOMIDE; MELPHALAN; NUCLEOSIDE ANALOG; PENTOSTATIN; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE; MONOCLONAL ANTIBODY;

ANTIANGIOGENIC ACTIVITY; ARTICLE; ASPERGILLOSIS; BLOOD VISCOSITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; DRUG WITHDRAWAL; HEMATOLOGIC DISEASE; HERPES SIMPLEX; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; INFECTION; LOW DRUG DOSE; LYMPHADENOPATHY; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PLASMA CELL DYSCRASIA; SALVAGE THERAPY; SENSORY NEUROPATHY; SPLENOMEGALY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT FAILURE; TUBERCULOSIS; WALDENSTROEM MACROGLOBULINEMIA; DRUG COMBINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOTHERAPY; REVIEW;

ALKYLATING AGENTS; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; WALDENSTROM MACROGLOBULINEMIA;

EID: 38149053983     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-007-0016-2     Document Type: Article

References (42)

1. Owen RG, Treon SP, Al-Katib A, et al.: Developing diagnostic criteria in Waldenstrom's macroglobulinemia. Semin Oncol 2003, 30:196-200.
2. Kyle RA, Treon SP, Alexanian R, et al. (2003) Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia. Semin Oncol 30:116-120
3. Gertz MA, Anagnostopoulos A, Anderson K, et al.: Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia. Semin Oncol 2003, 30:121-126.
4. Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP (2005) Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 23:1564-1577
5. Kyle RA, Greipp PR, Gertz MA, et al. (2000) Waldenstrom's macroglobulinaemia: A prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 108: 737-742 737-742
6. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. (2000) Waldenstrom's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol 18:214-226
7. Annibali O, Petrucci MT, Martini V, et al. (2005) Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: Results and cost analysis. Cancer 103: 582-587
8. Dhodapkar MV, Jacobson JL, Gertz MA, et al. (2003) Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003). Semin Oncol 30:220-225
9. Dimopoulos MA, Kantarjian H, Weber D, et al. (1994) Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12:2694-2698
10. Hellmann A, Lewandowski K, Zaucha JM, et al. (1999) Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstrom's macroglobulinemia. Eur J Haematol 63:35-41
11. Delannoy A, Van Den Neste E, Michaux JL, et al. (1999) Cladribine for Waldenstrom's macroglobulinaemia. Br J Haematol 104:933-934
12. Leblond V, Levy V, Maloisel F, et al. (2001) Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 98:2640-2644
13. Dimopoulos MA, Weber D, Delasalle KB, et al. (1995) Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors. Ann Oncol 6:49-52
14. Betticher DC, Hsu Schmitz SF, Ratschiller D, et al. (1997) Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenstrom's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). Br J Haematol 99:358-363
15. Anagnostopoulos A, Dimopoulos MA, Aleman A, et al. (2001) High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. Bone Marrow Transplant 27:1027-1029
16. Desikan R, Dhodapkar M, Siegel D, et al. (1999) High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia. Br J Haematol 105: 993-996
17. Dreger P, Glass B, Kuse R, et al. (1999) Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenstrom's macroglobulinaemia. Br J Haematol 106: 115-118
18. Anagnostopoulos A, Hari PN, Perez WS, et al. (2006) Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 12: 845-854
19. Tournilhac O, Leblond V, Tabrizi R, et al. (2003) Transplantation in Waldenstrom's macroglobulinemia - the French experience. Semin Oncol 30:291-296
20. Anderson LD Jr., Sandmaier BM, Maris MB, et al. (2006) Nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) for refractory Waldenstrom's macroglobulinemia (WM): Evidence for a Graft-versus-WM Effect. ASH Annu Meet Abstracts 108: 3034.
21. Gertz MA, Rue M, Blood E, et al. (2004) Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 45:2047-2055
22. Dimopoulos MA, Zervas C, Zomas A, et al. (2002) Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 20:2327-2333
23. Treon SP, Emmanouilides C, Kimby E, et al. (2005) Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol 16:132-138
24. Ghobrial IM, Fonseca R, Greipp PR, et al. (2004) Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: An Eastern Cooperative Oncology Group Study. Cancer 101: 2593-2598
25. Treon SP, Branagan AR, Hunter Z, et al. (2004) Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 15:1481-1483
26. Weber DM, Dimopoulos MA, Delasalle K, et al. (2003) 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 30:243-247
27. Dimopoulos MA, Hamilos G, Efstathiou E, et al. (2003) Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma 44:993-996
28. Tamburini J, Levy V, Chaleteix C, et al. (2005) Fludarabine plus cyclophosphamide in Waldenstrom's macroglobulinemia: Results in 49 patients. Leukemia 19:1831-1834
29. Tam CS, Seymour JF, Prince HM, et al. (2006) Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 91:1546-1550
30. Treon SP, Branagan A, Wasi P, et al. (2004) Combination therapy with rituximab and fludarabine in Waldenstrom's macroglobulinemia. ASH Annu Meet Abstracts 104:753.
31. Hensel M, Villalobos M, Kornacker M, et al. (2005) Pentostatin/ cyclophosphamide with or without rituximab: An effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma 6:131-135
32. Vargaftig J, Pegourie-Bandelier B, Mahe B, et al. (2006) Fludarabine plus cyclophosphamide and rituximab (RFC) in Waldenstrom' macroglobulinemia (WM): Results in 21 Patients (pts). ASH Annu Meet Abstracts 108:4727.
33. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. (2006) Primary treatment of Waldenstrom's macroglobulinemia (WM) with dexamethasone, rituximab and cyclophosphamide. ASH Annu Meet Abstracts 108:128.
34. Buske C, Dreyling MH, Eimermacher H, et al. (2004) Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment failure in first line treatment of patients with lymphomplasmocytoid/ic immunocytoma (LP-IC) - results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). ASH Annu Meet Abstracts 104:162.
35. Dimopoulos MA, Tsatalas C, Zomas A, et al. (2003) Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 30:265-269
36. Treon SP, Hunter Z, Patterson CJ, Branagan AR (2005) Thalidomide in combination with rituximab is active in Waldenstrom's macroglobulinemia and may overcome poor response determinants associated with rituximab monotherapy. ASH Annu Meet Abstracts 106:2442.
37. Treon SP, Patterson CJ, Hunter ZR, Branagan AR (2005) Phase II study of CC-5013 (Revlimid) and rituximab in Waldenstrom's macroglobulinemia: preliminary safety and efficacy results. ASH Annu Meet Abstracts 106:2443.
38. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. (2005) Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 90:1655-1658
39. Treon SP, Soumerai JD, Patterson CJ, et al. (2006) Bortezomib, dexamethasone and rituximab (BDR) is a highly active regimen in the primary therapy of Waldenstrom's macroglobulinemia: Planned interim results of WMCTG clinical trial 05-180. ASH Annu Meet Abstracts 108:2765.
40. Owen R, Rawstron AC, Osterborg A, et al. (2003) Activity of alemtuzumab (Mabcampath) in relapsed/refractory Waldenstrms macroglobulinemia. ASH Annu Meet Abstracts 102:2380.
41. Hunter ZR, Boxer M, Kahl B, et al. (2006) Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: Results of WMCTG trial 02-079. J Clin Oncol (Meeting Abstracts) 24:7523.
42. Treon SP, Gertz MA, Dimopoulos M, et al.: Update on treatment recommendations from the third international workshop on Waldenstrom's Macroglobulinemia. Blood 2006, 107:3442-3446.